Compare ASST & ANNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ASST | ANNX |
|---|---|---|
| Founded | 2020 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 685.1M | 730.4M |
| IPO Year | 2022 | 2020 |
| Metric | ASST | ANNX |
|---|---|---|
| Price | $10.63 | $5.86 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 6 |
| Target Price | $16.00 | ★ $16.50 |
| AVG Volume (30 Days) | ★ 3.0M | 2.4M |
| Earning Date | 05-14-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 82.56 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $633,489.00 | N/A |
| Revenue This Year | $294.91 | N/A |
| Revenue Next Year | $12.16 | $22,605.10 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 128.67 | N/A |
| 52 Week Low | $0.47 | $1.40 |
| 52 Week High | $13.40 | $7.18 |
| Indicator | ASST | ANNX |
|---|---|---|
| Relative Strength Index (RSI) | 58.05 | 55.27 |
| Support Level | $0.74 | $4.79 |
| Resistance Level | $11.27 | $6.50 |
| Average True Range (ATR) | 0.78 | 0.44 |
| MACD | -0.14 | 0.09 |
| Stochastic Oscillator | 89.47 | 66.67 |
Strive Inc is engaged in providing investment advisory, wealth management, and consulting services through its subsidiary. Its objectives is to (i) accumulate Bitcoin; (ii) increase Bitcoin-per-share; and (iii) outperform Bitcoin over the long run by deploying both beta Bitcoin treasury accumulation strategies and alpha investment strategies with the goal of beating Bitcoin's investment performance as the hurdle rate.
Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502 for Oral small molecule; and ANX009, for systemic autoimmune diseases.